|
Jul 30
|
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
|
|
Jul 29
|
Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
|
|
Jul 16
|
Cantor Fitzgerald Initiates Coverage of Bioventus (BVS) with an Overweight Rating
|
|
Mar 12
|
Bioventus Full Year 2024 Earnings: Beats Expectations
|
|
Mar 12
|
Q4 2024 Bioventus Inc Earnings Call
|
|
Mar 12
|
Bioventus Inc (BVS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ...
|
|
Mar 11
|
Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates
|
|
Mar 11
|
Bioventus: Q4 Earnings Snapshot
|
|
Mar 11
|
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 28
|
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025
|
|
Feb 13
|
Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?
|
|
Jan 3
|
BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business
|
|
Jan 3
|
Bioventus completes divestiture of its Advanced Rehabilitation business
|
|
Jan 2
|
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
|
|
Oct 9
|
Bioventus Inc (BVS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
|
|
Oct 1
|
Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
|
|
Sep 27
|
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
|
|
Aug 30
|
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
|
|
Aug 30
|
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
|
|
Aug 29
|
Bull Of The Day: Bioventus (BVS)
|